-

04:21:40 PM

IMMX Stock News

IMMX - Immix Biopharma Inc

12/13/22 8:00 AM

Nasdaq : IMMX

clinical triallow float

Immix Biopharma Announces Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial

In December 2022, the 15 th patient was dosed with IMX-110 IMX-110 clinical trial data expected to be released on a rolling basis beginning in Q1 2023; once dosing begins, patients undergo CT scans every 8 weeks to assess tumor response to IMX-110 IMX-110 monotherapy and IMX-110 combination

RHEA-AI

neutral

12/12/22 8:00 AM

Nasdaq : IMMX

clinical triallow float

ImmixBio Releases and Ships Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient Dosing

Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx) TM targeting oncology and immuno-dysregulated diseases, today announced that it has completed

RHEA-AI

neutral

11/11/22 8:00 AM

Nasdaq : IMMX

clinical trialfda approvallow float

Immix Biopharma Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinical Trial, Key Requirement for U.S. Food and Drug Administration Approval of Rare Pediatric Disease Priority Review Voucher

Enrolling pediatric patients in a clinical trial is a key requirement for FDA approval of a Priority Review Voucher (“PRV”) While their future value is uncertain, PRVs are transferable to other companies and have historically sold for $67 to $350 million according to a January 2020 report on drug

RHEA-AI

very positive

10/25/22 8:00 AM

Nasdaq : IMMX

conferencesclinical triallow float

Immix Biopharma to Present Milestones Achieved to Enable Kick-Off of 2 IMX-110 Clinical Trials at the 2022 ThinkEquity Conference on October 26

Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company

RHEA-AI

very positive

10/18/22 8:00 AM

Nasdaq : IMMX

clinical triallow float

ImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead Site

California Soft Tissue Sarcoma Site to lead expanded clinical site consortium Historically, high-enrolling lead site has enrolled 2-3 patients per month Clinical trial data expected to be released on a rolling basis beginning in Q1 2023; once dosing begins, patients undergo CT scans every 8 weeks

RHEA-AI

neutral

09/07/22 12:05 PM

Nasdaq : IMMX

clinical triallow float

ImmixBio Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical Trials

Scaled-up, proprietary GMP manufacturing process to be utilized in 2 clinical trials: 2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma (“STS”) 2022 planned combination IMX-110 + BeiGene anti-PD-1 tislelizumab Clinical Trial in advanced solid tumors A photo accompanying this

RHEA-AI

neutral

05/20/22 8:47 AM

Nasdaq : IMMX

low float

ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study

One cycle of IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug) In a connective tissue cancer Soft Tissue Sarcoma (STS) mice study, IMX-110 was compared against approved drugs IMX-110 is in clinical

RHEA-AI

very positive

05/09/22 8:00 AM

Nasdaq : IMMX

buybacklow float

Immix Biopharma Announces Share Repurchase Program

Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx) TM targeting oncology and immuno-dysregulated diseases, today announced that its board of directors

RHEA-AI

neutral

04/05/22 9:30 AM

Nasdaq : IMMX

low float

ImmixBio Management Discusses Key Milestones, Drug Development Timelines and the IMMX Advantage at IMMX Milestone Day Event Held on April 5, 2022

RHEA-AI

neutral

03/07/22 8:00 AM

Nasdaq : IMMX

low float

Immix Biopharma, Inc. Announces IMMX Milestone Day to be Held on April 5, 2022

Management plans to discuss current financial position, milestones, and new opportunities presented by current market volatility With $24.2 million gross proceeds from its December 2021 IPO, ImmixBio plans to commence 2 clinical trials in 2022 A photo accompanying this announcement is available at

RHEA-AI

neutral

Prev 1 2 3 4 Next

IMMX Data

IndustryResearch and Development in Biotechnology
Websitewww.immixbio.com
Security nameImmix Biopharma Inc
Issue typecs
SectorProfessional, Scientific, and Technical Services
Sic code2834

About Immix Biopharma Inc

ImmixBioTM is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases. Its proprietary System Multi-Action RegulaTors SMARxT Tissue-SpecificTM Platform produces drugs that accumulate at intended therapeutic sites at 3-5 times the rate of conventional medicines. ImmixBioTM TME Normalization™ Technology allows its drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the tumor micro-environment, or TME. ImmixBioTM has uncovered fundamental biological systems that link oncology and immuno-dysregulated diseases. In addition to oncology, its pipeline includes Tissue-Specific BiologicTM candidates to treat inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.